Moreover, current anti-angiogenic monoclonal antibodies targeting VEGFA, such as bevacizumab in combination with cancer immunotherapy have clinically benefited patients with non-small-cell lung cancer and hepatocellular carcinoma [61,62], suggesting that tumors with high FASN expression may be more suitable for targeting VEGFA in combination with immunotherapy. This evidence concerns the gene FASN and cancer.